Compare
Iwilfin vs. Vaniqa

Iwilfin (eflornithine) is a prescription medication used to help lower the risk of relapse in a rare cancer called high-risk neuroblastoma. It’s approved for children and adults who have responded to other treatments. The medication comes as a tablet that is taken twice a day, with or without food. Common side effects are hearing loss, ear infections, and fever.

• Reduce the risk of relapse in children and adults with high-risk neuroblastoma that has some response to previous treatment

• Ear infections (32%)
• Diarrhea (15%)
• Cough (15%)
• Sinus infections (13%)
• Pneumonia (12%)
• Allergies (11%)
• Fever (11%)
• Vomiting (11%)
• Pink eye (11%)

• Low blood cell counts
• Liver problems
• Hearing loss
• Harm to unborn babies

Vaniqa (eflornithine) is a prescription cream that's used to reduce unwanted facial hair growth in women. Vaniqa (eflornithine) belongs to a group of medications called ornithine decarboxylase inhibitors (ODC). It blocks a protein called ODC in the skin to slow down hair growth. The cream is applied on the face and under the chin twice a day, with at least 8 hours in between. Potential side effects include acne and stinging skin.

Note: Vaniqa (eflornithine) was discontinued in 2023. An alternative medication with the same active ingredient is the brand Florexa, which is still available.

• Unwanted facial hair in women

• Acne (11-21%)
• Razor bumps (5-16%)
• Stinging skin (4-8%)
• Headache (4%)
• Burning skin (4%)
• Itching (3-4%)
• Tingling skin (2-4%)
• Dry skin (2-3%)
• Rash (2-3%)
• Redness (1-3%)
• Skin irritation (1-2%)

• For external use only